Logo

Baxter's Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA's Approval for Diabetes Mellitus

Share this

Baxter's Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA's Approval for Diabetes Mellitus

Shots:

  • The US FDA has granted approval to Myxredlin as the first ready-to-use insulin for IV infusion in the hospital with an extended shelf-life of 30 days @25◦C or 24 mos. if refrigerated @2-8◦C
  • Myxredlin utilizes Baxter's Galaxy container technology which is a non-PVC and non-DEHP system enabling premixed medicines to have a longer shelf life at room temperature
  • Myxredlin (insulin human in 0.9% sodium chloride injection) is available in a standardized concentration of 100 units/100 mL in a flexible plastic container indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus

Click here to read full press release/ article | Ref: Baxter | Image: Baxter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions